Metabolic clearance of physicochemically diverse pharmaceuticals in cultured fish hepatocytes
Environmental Toxicology and Chemistry · 2025
DOI: 10.1093/etojnl/vgaf193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environmental Toxicology and Chemistry, 2025. Verfasst von Chrisna Matthee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biosciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, United Kingdom. Hauptthemen laut MEDLINE: Hepatocytes, Oncorhynchus mykiss, Water Pollutants, Chemical. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Prioritisation and Risk Evaluation of Medicines in the EnviRonment, Innovative Medicines Initiative 2 Joint Undertaking, European Union's Horizon 2020.
Abstract (Originalsprache)
Fish are inherently susceptible to the exposure and effects of pharmaceutical pollutants in aquatic ecosystems and are often used to quantify the bioaccumulation and effects of active pharmaceutical ingredients (APIs) during environmental risk assessment. While metabolism and transport are major determinants of an API’s ability to bioaccumulate, a sound understanding of these processes in fish and how they compare to those seen in mammals is lacking. Primary hepatocyte cultures comprise a promising in vitro tool that can be applied to help fill these knowledge gaps, while also contributing to the refinement, reduction, and eventual replacement of animal testing in ecotoxicology. Here we apply the well-established rainbow trout (Oncorhynchus mykiss) primary hepatocyte monolayer model to assess the hepatic clearance of five diverse APIs, namely propranolol, quetiapine, mycophenolic acid, clozapine, and olaparib. We also explore the effects of these APIs on the transcription of selected transport- and metabolism-related genes (abcb1, mrp2, cyp1a, and cyp3a) and metabolic enzyme (cytochrome P4501A) activity in fish hepatocytes. The hepatocyte monolayers were found to clear all the studied APIs, with the majority showing comparable extrapolated clearance rates to those measured in humans. Transcript profiling and enzyme activity assay results, on the other hand, showed both differences and similarities to currently available human data, emphasizing the fact that the clearance and effects of APIs on metabolic and transport systems cannot be assumed to be directly comparable between fish and humans. Our data further support the good utility and replicability of the rainbow trout hepatocyte monolayer model and, in turn, its use in hazard identification and building risk profiles for APIs with wide-ranging properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biosciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, United Kingdom.
ORCID-Profile: Chrisna Matthee
Förderung
- Prioritisation and Risk Evaluation of Medicines in the EnviRonment
- Innovative Medicines Initiative 2 Joint Undertaking
- European Union's Horizon 2020
- European Federation of Pharmaceutical Industries and Associations
- European Union’s Horizon 2020
Zitieren
APA
Matthee, C., Brown, A. R., Lange, A., Trznadel, M., & Tyler, C. R. (2025). Metabolic clearance of physicochemically diverse pharmaceuticals in cultured fish hepatocytes. Environmental Toxicology and Chemistry. https://doi.org/10.1093/etojnl/vgaf193
Vancouver
Matthee C, Brown AR, Lange A, Trznadel M, Tyler CR. Metabolic clearance of physicochemically diverse pharmaceuticals in cultured fish hepatocytes. Environmental Toxicology and Chemistry. 2025. doi:10.1093/etojnl/vgaf193
BibTeX
@article{Matthee2025,
author = {Matthee, Chrisna and Brown, A Ross and Lange, Anke and Trznadel, Maciej and Tyler, Charles R},
title = {Metabolic clearance of physicochemically diverse pharmaceuticals in cultured fish hepatocytes},
journal = {Environmental Toxicology and Chemistry},
year = {2025},
doi = {10.1093/etojnl/vgaf193}
}
EUVIMED